{"organizations": [], "uuid": "cea95b67a83dea65096b11badebb20702494ed6a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 11, "shares": 11, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s3.reutersmedia.net/resources/r/?m=02&d=20180312&t=2&i=1240023380&w=1200&r=LYNXNPEE2B0DM", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/us-astrazeneca-cancer/astrazeneca-sees-pivotal-lung-cancer-trial-results-later-in-2018-idUSKCN1GO0O0", "country": "US", "domain_rank": 408, "title": "AstraZeneca sees pivotal lung cancer trial results later in 2018", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-12T09:36:00.000+02:00", "replies_count": 0, "uuid": "cea95b67a83dea65096b11badebb20702494ed6a"}, "author": "", "url": "https://www.reuters.com/article/us-astrazeneca-cancer/astrazeneca-sees-pivotal-lung-cancer-trial-results-later-in-2018-idUSKCN1GO0O0", "ord_in_thread": 0, "title": "AstraZeneca sees pivotal lung cancer trial results later in 2018", "locations": [], "entities": {"persons": [{"name": "louise heavens", "sentiment": "none"}, {"name": "ben hirschler", "sentiment": "none"}], "locations": [{"name": "mystic", "sentiment": "none"}, {"name": "london", "sentiment": "none"}, {"name": "london", "sentiment": "none"}], "organizations": [{"name": "astrazeneca", "sentiment": "negative"}, {"name": "imfinzi", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "LONDON (Reuters) - AstraZeneca now expects a key lung cancer study of two immunotherapy drugs to produce overall survival results in the second half of 2018, rather than the first half.\nFILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London April 28, 2014. REUTERS/Stefan Wermuth/File Photo The Phase III trial, known as Mystic, is testing Imfinzi on its own and in combination with tremelimumab, and the drugmaker noted in a brief statement on Monday that it was driven by clinical events among patients involved.\nFirst results from Mystic disappointed investors last July when AstraZenecaâ€™s two drugs proved no more effective at stopping disease progression than chemotherapy, sending its shares tumbling.\nReporting by Ben Hirschler, editing by Louise Heavens\n ", "external_links": [], "published": "2018-03-12T09:36:00.000+02:00", "crawled": "2018-03-12T10:08:23.032+02:00", "highlightTitle": ""}